The vaccine generated an immune response against C. diff toxins A and B, the ones that are largely responsible for CDI, which is a bacterial infection that can cause life-threatening gut inflammation and diarrhea.
The results put Sanofi ahead of Pfizer (PFE) and Valneva for preventing CDI.
Sanofi is now enrolling 15,000 participants in 17 countries for a Phase III trial.
Over 336,000 Americans a year become infected with C. difficile, and the infection is becoming ever more prevalent in healthcare facilities, partly due to the overuse of antibiotics. (PR)